Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
subsidiary Priovant Therapeutics had started enrolling patients in a Phase 2b/3 trial of brepocitinib for lichen planopilaris (LPP). LPP is a severe inflammatory hair loss condition and brepocitinib treats that inflammation. Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure Roivant said that the trial structure starts with a 72-patient Phase 2b segment to refine dosing and endpoints, then flows directly into a 270-patient Phase 3 without interruption. It added that the primary endpoint being targeted is an Investigator's Global Assessment (IGA) score of 0 or 1 with a two-point reduction. This is a more defined measure than previous LPP studies, the company noted. Priovant CEO Ben Zimmer said brepocitinib's mechanism is well-suited for LPP. This is because the disease is driven by TH1-polarized T-cell activity, which is the exact biology the drug is designed to suppress. Separately, Roivant's Immunovant unit reported that batoclimab failed to meet the primar
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]USA TODAY
- Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript [Seeking Alpha]Seeking Alpha
- Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint [Yahoo! Finance]Yahoo! Finance
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 4/10/26 - Form 4
- 4/8/26 - Form 144
- 4/2/26 - Form 4
- ROIV's page on the SEC website